新冠特效藥概念股集體走強:君實生物AH股均漲超14%
格隆匯1月17日丨港A兩地新冠特效藥概念股集體走強,其中,君實生物AH股齊步拉昇,A股一度漲近15%報87.66元,H股一度漲超14%至58.95港元。奧密克戎新冠病毒繼續蔓延,全球確診病例數仍持續攀升。君實生物在新冠藥物研發進展方面備受市場關注。目前,君實生物擁有中和抗體類埃特司韋單抗(etesevimab,JS016)和巴尼韋單抗(bamlanivimab)以及JS026注射液;小分子口服藥為口服核苷類VV116。埃特司韋單抗和巴尼韋單抗雙抗體療法已獲得美國FDA緊急使用授權(EUA);JS026已獲國家藥品監督管理局批准進入臨牀試驗。另外,公司曾於2021年12月31日宣佈烏茲別克斯坦已批准新冠口服藥VV116的緊急使用授權。同時,該藥物也正在中國同步開展臨牀研究。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.